In addition to documenting information about pain status, the patients' gender, age, employment status, marital status, and level of education were noted. Other data included presenting diagnosis, past or present diagnoses associated with chronic pain, and medications associated with chronic pain prescribed before or after admission to Hope Clinic.
To determine the prevalence of CNMP within the referring FHS, a retrospective report of chronic pain specific ICD-10 G89 codes, “Acute pain, not elsewhere classified,” was requested and analyzed. The G89 code set contains 13 possible ICD-10 codes, and all were requested; only three codes specific to CNMP were represented in the data: G89.28 “Other chronic post procedural pain”; G89.29 “Other chronic pain”; and G89.4 “Chronic pain syndrome.” A comparison of prevalence rates for Hope Clinic and the referring FHS was completed.
Phase 3: Postassessment. Information from Phases 1 and 2 was compiled and analyzed. Hope Clinic's existing resources were evaluated, a secondary literature review was performed, and an action plan was formulated to initiate the process of CNMP management within Hope Clinic. Recommendations were provided to the board of directors.
INADEQUATE PAIN MANAGEMENT
In Phase I, key stakeholders at Hope Clinic were asked for their input. Response themes developed from interviews were: 1) a desire for continued and expanded services provided for community and resource-poor individuals; 2) interventions to strengthen institutional relationships; and 3) the formulation of achievable recommendations that consider facility and institutional resources.
During Phase 1, it was discovered that data were absent on the presence of CNMP, pain intensity, and the degree to which pain interfered with activities of daily living for patients within Hope Clinic; data on the prevalence of CNMP in the referring FHS also were lacking. Data either had not been collected or had not been analyzed. Likewise, basic demographic information was absent.
During the 3-month project implementation period, 38 patients presented to Hope Clinic. Of these, five were not eligible to participate (three were under age 18; two did not return after the first visit). Thus, 33 patients (N = 33) were included in data analysis, of whom 17 met criteria for CNMP. Demographic information for these patients is presented in Table 2.
Table 3 notes the chronic pain grades reported by participants. Of the 33 participants, 25 (75.8%) experienced a Grade 1 pain or higher. Among the 25 patients with gradable pain, 19 (76%) reported Grade 2 or higher, denoting high pain intensity with moderate-to-severe interference. Patients whose pain was categorized as nonpersistent (n = 16, 48.5%) were less likely to experience high-intensity pain, which resulted in moderate-to-severe activity interference (n = 5; 31.4%), compared with those who had persistent pain (n = 14; 82.3%). Seventeen (n = 17) patients experienced pain for 90 days or more, thus, the prevalence of CNMP was 51.51% (Table 3). The most common concurrent medical diagnoses were CVA in 11 patients (64.70%) and hypertension in 3 (17.65%) (Table 2).
The distribution of pain medications for patients with CNMP was analyzed. A total of 34 medications were taken for pain. Of these, 10 patients (29.4%) were taking nonnarcotic analgesics. Other medications included narcotic analgesic combinations, for example, Norco (n = 5; 14.7%); anticonvulsants, for example, Keppra (levetiracetam) (n = 4; 11.8%); and antidepressants, for example, Trazodone (n = 3; 8.8%). Five patients (14.7%) were not taking pain medications.
The prevalence of nonemergency department FHS outpatients with CNMP (G89 codes) over 3 months was 1.00% (n = 1,290 out of 128,601), whereas the prevalence for all outpatient emergency department patients with G89 codes was 0.16% (n = 203). Information about CNMP patients for each hospital is available online as SDC at http://links.lww.com/NCF-JCN/A61.
RECOMMENDATIONS FOR PAIN MANAGEMENT
Based on the needs assessment, the following recommendations were made:
- Integrate the collection of demographic data, as well as the GCPS into the initial assessment for all patients admitted to the clinic.
- Administer the GCPS at consistent intervals to establish the “effectiveness of treatments in reducing pain and pain-related disability” (IOM, 2011, p. 6).
- Develop relationships with patients' primary care providers to discuss evidence-based medication management and ensure that the most effective pain medications are used consistently.
- Implement evidence-based cognitive behavioral strategies as part of a CREATION-based treatment plan to assist patients in changing maladaptive pain behaviors, enhancing personal relationships, and developing positive coping strategies (Heapy et al., 2016; Heutink et al., 2012; IOM, 2011).
- Ensure that patients with CNMP are:
- Evaluated for both insomnia and depression, as treatment of these conditions may have a beneficial impact on pain and other comorbidities.
- Evaluated for the presence of life stressors and extent of coping skills, as these provide insight into the onset and/or maintenance of insomnia, CNMP, and depression (Finan & Smith, 2013, p. 180).
- Provided a printed copy of “Psychological and Behavioral Treatments for Insomnia” (Morin et al., 2006) to help with behavioral modifications to decrease insomnia and depression.
- The FHS should engage in a quality-improvement project to optimize the use of correct ICD-10 codes, which is likely to capture lost revenue and improve patient outcomes.
CREATION MODEL EVIDENCE-BASED INTERVENTIONS
Demographic information is important to a comprehensive understanding of population characteristics so providers can identify patients with CNMP; develop a targeted approach to managing symptoms appropriately, and reduce pain-related disabilities (Mills, Torrance, & Smith, 2016; van Hecke, Torrance, & Smith, 2013). Clinic patients who met the criteria for CNMP had the following characteristics: female, married, of African American or Hispanic descent, unemployed, in their 50s, and some level of college education. In other studies, CNMP patients most commonly were female, married, of older age, unemployed, and educated at high school level or less (IOM, 2011; van Hecke et al.).
These findings differ from the literature on principal diagnosis and medication regimens. The three most common CNMP-associated diagnoses are lower back pain, migraine, and neck pain (Gatchel et al., 2018). Within Hope Clinic, the primary diagnosis of patients with CNMP was CVA, most likely because the clinic offers only occupational therapy and rehabilitation services, where the primary goal is to help patients recover or develop skills for daily living and working.
We chose to utilize three principles from the CREATION Health Model (Sidebar 1) in our recommendations for improving the management of CNMP control within Hope Clinic: Choice in behavioral strategies; Rest to refuel and refocus; and Interpersonal relationship development to assist in healing. These biblical principles are supported in Psalm 55:22 and Matthew 11:28.
Three evidence-based interventions were identified and mission aligned with both the Hope Clinic and the FHS to assure that the interventions share the same trajectory (Daft, 2015): cognitive behavioral strategies; psychological and behavioral treatments for insomnia; and careful assessment and observation for patients experiencing dysfunctional social environments or complete lack of support systems.
Evidence is supportive of cognitive behavioral strategies as an important component of an effective chronic pain treatment plan. Primary benefits result from modification of maladaptive pain behaviors and assisting patients in the development of positive coping strategies (Care Committee on Advancing Pain Research & Institute of Medicine, 2010; Heapy et al., 2016; Heutink et al., 2012).
The prevalence of insomnia in patients presenting with chronic pain is estimated at 50% to 80% (Alföldi, Dragioti, Wiklund, & Gerdle, 2017). Depression is frequently comorbid with chronic pain and insomnia. These conditions are thought to be “mutually interacting, each increasing the risk for the emergence and/or exacerbation of the other” (Finan & Smith, 2013, p. 173). Patients with centrally mediated chronic pain, as is the case with many CVA patients, are more likely to experience depression and insomnia (Finan & Smith). Therefore, recommendation was made that Hope Clinic patients experiencing chronic pain receive psychological and behavioral treatments for insomnia.
Patients with chronic pain who have a strong social support system experience a reduction in pain severity and are better adjusted. It has been postulated that pain can be socially modulated (Krahé, Springer, Weinman, & Fotopoulou, 2013). Social support is considered an external resource in cognitive-behavioral approaches for pain management. However, social interactions can also be dysfunctional as a result of invalidation, ostracism, and stigmatization. Negative social interactions can impede the rehabilitation process and create a perception of heightened pain severity (Karos, 2017; Waugh, Byrne, & Nicholas, 2014). It was recommended that clinic staff receive education regarding the impact of positive or negative social contexts, to observe for dysfunctional social environments, and to “create a safe and validating environment for patients that facilitates understanding and recovery from pain” (Karos, p. 293).
APPROPRIATE USE OF MEDICATION
CNMP syndromes associated with CVA may include central poststroke pain, peripheral neuropathic pain, pain from spasticity, and pain from shoulder subluxation (O'Donnell et al., 2013). Recommended drug treatment has traditionally relied on antidepressants and antiepileptic medications as first-line therapy. Recent safety concerns have led to transition of opiates from a first-line to a third-line agent. Currently, however, nonnarcotic analgesics are not recommended for the treatment of neuropathic pain, as this type of pain responds poorly to this class of medications (Finnerup et al., 2015).
The medication regimens of CNMP patients within the Hope Clinic deviated significantly from standard treatment recommendations—a finding supported in the literature (Torrance et al., 2013). Of those taking medications specifically for pain, the primary classification represented was nonnarcotic analgesics (29.4%), which are generally ineffective. Narcotic analgesics, now considered third-line agents, were the second most common medication identified (14.7%). Antidepressants and anticonvulsants, which are first-line agents, were only used in 8.8% and 11.8% of patients, respectively.
Of greatest concern were patients identified as experiencing CNMP but not taking any medication to assist in management. Further exploration into nonpharmacologic strategies for pain management used by these patients is needed. Sidebar 2 offers the latest updates for pain assessment and management.
Study limitations include the selection of a center that offered a single-service line (occupational/rehabilitation therapy), and using only ICD-10 G89 codes to identify CNMP in the hospital system. This resulted in the compilation of a small, homogenous sample. Additionally, although medication lists were obtained and analyzed, no contact was made with primary care providers. Interprofessional collaboration would have provided a more effective pain-management approach. Finally, the use of ICD-10 G89 codes as the exclusive means of pain identification may have resulted in an inexact representation of the true prevalence of CNMP within the referring FHS. Relying on an emergency department or outpatient-facility staff to identify and report patients experiencing CNMP may have resulted in an increase in the number of identified patients. These limitations restrict generalizability.
The crucial role of nurses is to provide appropriate assessment and medical management of patients with CNMP and help avoid improper pain management. Poor pain management adversely affects patients physically, psychologically, and socially. CNMP management should be diagnosis-specific, patient-centered, and evidence-based. CREATION health strategies can be implemented based on diagnosis and patient.
Nurses, locally and globally, are confronted with a high prevalence of CNMP and inadequate identification methods for CNMP, prevalence of pain and care disparities in selected populations, inadequate management of CNMP, and a growing opioid epidemic (IOM, 2011). This constellation of challenges requires a patient-centered approach that nurses are uniquely suited to address. Study findings support that a clear understanding of a given patient population must guide recommendations for patient care.
The authors would like to thank Cathryn D. Evans, BSc, for providing editorial assistance.
The CREATION Health Model
The CREATION Health Model is Florida Hospital's vision for whole patient care and wellness. This model presents a unique opportunity to explore a more holistic pain management strategy, as recommended by the Care Committee on Advancing Pain Research & the Institute of Medicine (IOM, 2011, p. 129). This faith-based wellness plan advocates for the practice of eight principles, represented by the letters in the word creation, to assist people to live healthier, happier lives:
- Choice encourages individuals to make careful, well-thought-out choices that are aligned with personal goals to improve outcomes;
- Rest is addressed as a powerful tool for regeneration and improved health;
- Environment focuses on the impact of our external space and its impact on mood and health;
- Activity is the interrelation of mental and physical activity and the importance of both for personal health;
- Trust stresses a relationship with God and its positive impact on health and life expectancy;
- Interpersonal Relationships are important to maintain or improve quality of life and promote health;
- Outlook is the impact of a positive perspective and learned optimism on health and healing;
- Nutrition impacts dietary choices that lay the foundation for improved health, healing, and longevity.
Note. Adapted from Florida Hospital System (n.d.) and Reed & Wallace (2007). Used with permission.
Updated Guidelines for Pain Assessment and Management
The opioid prescribing and addiction crises have resulted in significant changes in the standard of care for pain assessment and management. Opioids are a class of drugs derived from the opium poppy plant to relieve pain and achieve relaxation. Opioids include approved prescribed medications, such as morphine, hydrocodone, or oxycodone, and illicit and illegal drugs, such as heroin. Persons with drug addiction tendencies can fall into illicit drug use or abuse the use of prescription medications in an effort to relieve chronic pain. Increasing our understanding of the standards of care associated with pain management can not only treat pain, but help prevent addiction. Below are updates from major stakeholders in pain management.
American Pain Society (APS). In 2009, the APS published clinical guidelines for the use of opioids in chronic noncancer pain. While acknowledging that evidence was not always strong for these practice guidelines, broad recommendations were made, including: appropriate use of opioids and dosing; risk stratification; informed consent with management plans; titration and discontinuation of opioids; prevention and management of side effects; safety related to driving and work; and developing opioid policies and procedures (Chou et al., 2009). Harm–benefit ratio should be carefully considered, and a written management plan implemented. A therapeutic opiate trial should be considered, along with individualized dosing and management, particularly in high-risk persons.
American Society for Pain Management Nursing (ASPMN). ASPMN has published several position statements, the most recent in collaboration with the APS (Drew, Gordon, Morgan, & Manworren, 2018), which discusses the role of the nurse in appropriate dosing of prn pain medications. The society, whose mission is to promote best practices in pain management nursing, said they “support safe medication practices and the appropriate use of PRN range orders for opioid analgesics in the management of pain” (p. 207). An earlier position statement (Pasero, Quinlan-Colwell, Rae, Broglio, & Drew, 2016) stated that ASPMN did not support patient-reported pain intensity as a sole criterion for opioid prescription, but that holistic assessment was needed to avoid negative patient outcomes.
Centers for Disease Control and Prevention (CDC). The CDC (Dowell, Haegerich, & Chou, 2016) updated its guidelines for opiate prescribing to focus on three areas: determining when to use opioids for chronic pain; appropriate dosing, treatment, and monitoring; and risk assessment/addressing side effects or harm. There are 12 recommendations. Of particular note are: Dose recommendations, with a caution note, are lower in the new guidelines, due to the increased risk of harm and death with even low doses, such as daily 20 to 50 morphine milligram equivalents; the benefit–harm ratio should be evaluated at least every 3 months; concurrent opiate and benzodiazepine therapy should be avoided. These revised guidelines emphasize safer care and risk assessment.
The Joint Commission (TJC). In January 2018, TJC added revisions to its standards for accredited hospitals to specifically require the following (2018, para 3):
- Establish a clinical leadership team;
- Actively engage medical staff and hospital leadership in improving pain assessment and management, including strategies to decrease opioid use and minimize risks associated with opioid use;
- Provide at least one nonpharmacologic pain treatment modality;
- Facilitate access to prescription drug monitoring programs;
- Improve pain assessment by concentrating more on how pain is affecting patients' physical function;
- Engage patients in treatment decisions about their pain management;
- Address patient education and engagement, including storage and disposal of opioids to prevent these medications from being stolen or misused by others;
- Facilitate referral of patients addicted to opioids to treatment programs.
Common threads run throughout these organizations, practice guidelines, and standards of care related to pain management and opioid treatment. These include risk assessment, weighing risk-benefit, not using opioids as single therapy for chronic pain, appropriate prescribing at lower doses, addressing adverse effects of opioids, closer monitoring, exploring nonpharmacologic options, and safety considerations.
—Kristen L. Mauk, Contributing Editor
Instructions for Taking the CE Test Online
- Read the article. The test for this CE activity can be taken online at www.NursingCenter.com/CE/CNJ. Find the test under the article title. Tests can no longer be mailed or faxed. You will need to create a username and password and log in to your free personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
- There is only one correct answer for each question. A passing score for this test is 16 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
- This CE test also is available for viewing at www.journalofchristiannursing.com in the table of contents for this issue under
- Visit www.nursingcenter.com for other CE activities and your personalized CE planner tool.
- For questions, contact Lippincott Professional Development: 1-800-787-8985.
Registration Deadline: March 5, 2021.
Disclosure Statement: The authors and planners have disclosed that they have no financial relationships related to this article.
Lippincott Professional Development will award 1.5 contact hours for this continuing nursing education activity.
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider-approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida, CE Broker #50-1223.
Payment and Discounts:
- The registration fee for this test is $17.95 for nonmembers, $12.95 for NCF members.
For additional continuing education articles on the topic of pain management go to NursingCenter.com/CE.
Alföldi P., Dragioti E., Wiklund T., Gerdle B. (2017). Spreading of pain and insomnia in patients with chronic pain
: Results from a national quality registry (SQRP). Journal of Rehabilitation Medicine
, 49(1), 63–70.
Altschuld J. W., Watkins R. (2014). A primer on needs assessment
: More than 40 years of research and practice. New Directions for Evaluation
, 2014(144), 5–18. doi:10.1002/ev.20099
Care Committee on Advancing Pain Research, & Institute of Medicine. (2010). Relieving pain in America: A blueprint for transforming prevention, care, education, and research
. Washington, DC: National Academies Press.
Cheatle M. D. (2011). Depression, chronic pain
, and suicide by overdose: On the edge. Pain Medicine
, 12(Suppl. 2), S43–S48. doi:10.1111/j.1526-4637.2011.01131.x
Chou R., Fanciullo G. J., Fine P. G., Adler J. A., Ballantyne J. C., Davies P., ..., Miaskowski C. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain
, 10(2), 113–130. doi:10.1016/j.jpain.2008.10.008
Daft R. L. (2015). Creating vision and strategic direction. The leadership experience
(6th ed.). Independence, KY: Cengage Learning.
Dowell D., Haegerich T. M., Chou R. (2016). CDC guideline for prescribing opioids for chronic pain
—United States, 2016. Journal of the American Medical Association
, 315(15), 1624–1645. doi:10.1001/jama.2016.1464
Drew D. J., Gordon D. B., Morgan B., Manworren R. C. B. (2018). “As-Needed” range orders for opioid analgesics in the management of pain: A consensus statement of the American Society for Pain Management Nursing
and the American Pain Society. Pain Management Nursing
, 19(3), 207–210. doi:10.1016/j.pmn.2018.03.003
Fayaz A., Croft P., Langford R. M., Donaldson L. J., Jones G. T. (2016). Prevalence of chronic pain
in the UK: A systematic review and meta-analysis of population studies. BMJ Open
, 6(6), e010364. doi:10.1136/bmjopen-2015-010364
Ferrer-Peña R., Gil-Martínez A., Pardo-Montero J., Jiménez-Penick V., Gallego-Izquierdo T., La Touche R. (2016). Adaptation and validation of the Spanish version of the graded chronic pain
scale. Reumatología Clínica (English Edition)
, 12(3), 130–138. doi:10.1016/j.reuma.2015.07.004
Finan P. H., Smith M. T. (2013). The comorbidity of insomnia, chronic pain
, and depression: Dopamine as a putative mechanism. Sleep Medicine Reviews
, 17(3), 173–183. doi:10.1016/j.smrv.2012.03.003
Finnerup N. B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R. H., ..., Wallace M. (2015). Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. The Lancet. Neurology
, 14(2), 162–173. doi:10.1016/S1474-4422(14)70251-0
Garcia A. M. (2013). State laws regulating prescribing of controlled substances: Balancing the public health problems of chronic pain
and prescription painkiller abuse and overdose. The Journal of Law, Medicine & Ethics
, 41(Suppl. 1), 42–45. doi:10.1111/jlme.12037
Gatchel R. J., Reuben D. B., Dagenais S., Turk D. C., Chou R., Hershey A. D., ..., Horn S. D. (2018). Research agenda for the prevention of pain and its impact: Report of the work group on the prevention of acute and chronic pain
of the Federal Pain Research Strategy. The Journal of Pain
, 19(8), 837–851. doi:10.1016/j.jpain.2018.02.015
Goldberg D. S., McGee S. J. (2011). Pain as a global public health priority. BMC Public Health
, 11, 770. doi:10.1186/1471-2458-11-770
Heapy A. A., Higgins D. M., LaChappelle K. M., Kirlin J., Goulet J. L., Czlapinski R. A., ..., Kerns R. D. (2016). Cooperative pain education and self-management (COPES): Study design and protocol of a randomized non-inferiority trial of an interactive voice response-based self-management intervention for chronic low back pain. BMC Musculoskeletal Disorders
, 17(1), 85. doi:10.1186/s12891-016-0924-z
Heutink M., Post M. W., Bongers-Janssen H. M., Dijkstra C. A., Snoek G. J., Spijkerman D. C., Lindeman E. (2012). The CONECSI trial: Results of a randomized controlled trial of a multidisciplinary cognitive behavioral program for coping with chronic neuropathic pain after spinal cord injury. Pain
, 153(1), 120–128. doi:10.1016/j.pain.2011.09.029
Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education, and research
. Washington, DC: National Academies Press. doi:10.17226/13172
Jackson T. P., Stabile V. S., McQueen K. K. (2014). The global burden of chronic pain
. ASA Newsletter
, 78(6), 24–27.
Janevic M. R., McLaughlin S. J., Heapy A. A., Thacker C., Piette J. D. (2017). Racial and socioeconomic disparities in disabling chronic pain
: Findings from the health and retirement study. The Journal of Pain
, 18(12), 1459–1467. doi:10.1016/j.jpain.2017.07.005
Karos K. (2017). Hell is other people: On the importance of social context in pain research. European Health Psychologist
, 19(1), 290–296.
Krahé C., Springer A., Weinman J. A., Fotopoulou A. (2013). The social modulation of pain: Others as predictive signals of salience—A systematic review. Frontiers in Human Neuroscience
, 7, 386.
Mills S., Torrance N., Smith B. H. (2016). Identification and management of chronic pain
in primary care: A review. Current Psychiatry Reports
, 18(2), 22. doi:10.1007/s11920-015-0659-9
Morin C. M., Bootzin R. R., Buysse D. J., Edinger J. D., Espie C. A., Lichstein K. L. (2006). Psychological and behavioral treatment of insomnia: Update of the recent evidence (1998-2004). Sleep
, 29(11), 1398–1414.
O'Donnell M. J., Diener H. C., Sacco R. L., Panju A. A., Vinisko R., Yusuf S. (2013). Chronic pain
syndromes after ischemic stroke: PRoFESS trial. Stroke
, 44(5), 1238–1243. doi:10.1161/strokeaha.111.671008
Pasero C., Quinlan-Colwell A., Rae D., Broglio K., Drew D. (2016). American Society for Pain Management Nursing
position statement: Prescribing and administering opioid doses based solely on pain intensity. Pain Management Nursing
, 17(3), 170–180. doi:10.1016/j.pmn.2016.03.001
Reed M. M. D., Wallace D. K. (2007). The CREATION health breakthrough: 8 essentials to revolutionize your health physically, mentally, and spiritually
(1st ed.). New York, NY: Center Street.
Torrance N., Ferguson J. A., Afolabi E., Bennett M. I., Serpell M. G., Dunn K. M., Smith B. H. (2013). Neuropathic pain in the community: More under-treated than refractory? Pain
, 154(5), 690–699. doi:10.1016/j.pain.2012.12.022
Turk D. C., Melzack R. (2011). Handbook of pain assessment
. New York, NY: Guilford.
van Hecke O., Torrance N., Smith B. H. (2013). Chronic pain
epidemiology and its clinical relevance. British Journal of Anaesthesia
, 111(1), 13–18.
Von Korff M., Ormel J., Keefe F. J., Dworkin S. F. (1992). Grading the severity of chronic pain
, 50(2), 133–149. doi:10.1016/0304-3959(92)90154-4
Waugh O. C., Byrne D. G., Nicholas M. K. (2014). Internalized stigma in people living with chronic pain
. The Journal of Pain
, 15(5), 550.e1–550.e10.
Webster L. R. (2014). Pain and suicide: The other side of the opioid story. Pain Medicine
, 15(3), 345–346. doi:10.1111/pme.12398
chronic pain; CREATION Health Model; needs assessment; nursing; occupational therapy; opioid abuse; outpatients; pain management
Supplemental Digital Content
© 2019 by InterVarsity Christian Fellowship